TITLE

Buprenorphine transdermal system has REMS

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1306
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that Purdue Pharma LP has received the marketing approval for its buprenorphine transdermal system, Butrans, from the Food and Drug Administration (FDA), along with its risk evaluation and mitigation strategy (REMS) in the U.S. on July 1, 2010.
ACCESSION #
52946768

 

Related Articles

  • FDA approves reformulated OxyContin to discourage abuse, cut overdoses. Currie, Donya // Nation's Health;Jul2013, Vol. 43 Issue 5, p7 

    The article reports on the approval by U.S. Food and Drug Administration officials of a new formulation of the painkiller OxyContin manufactured by the pharmaceutical company Purdue Pharma L.P. in order to reduce its drug abuse and misuse.

  • Purdue calls ad citation a 'misunderstanding'. Dickinson, James D. // Medical Marketing & Media;Mar2003, Vol. 38 Issue 3, p26 

    Reports on the statement referencing the Food and Drug Administration Warning Letter of Purdue Pharma in the U.S. Misconception of the safety information of the advertisement; Reduction of drug safety risk; Promotion of OxyContin for unapproved uses.

  • OxyContin Labeling Updated.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-26 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved the labeling of reformulated OxyContin drug from Purdue Pharma LP.

  • Abuse-Deterrent Hydrocodone Gets OK.  // Chain Drug Review;12/8/2014, Vol. 36 Issue 20, p93 

    The article reports that the U.S. Food & Drug Administration (FDA) has approved the Hysingla ER extended-release tablets CII from Purdue Pharma LP.

  • FDA Strengthens Warnings for OxyContin.  // FDA Consumer;Sep/Oct2001, Vol. 35 Issue 5, p21 

    Reports on the decision of the United States Food and Drug Administration to strengthen the warnings and precautions sections in the labeling of OxyContin controlled-release tablets. Content of OxyContin; Information on an initiative taken by Purdue Pharma, maker of the drug, to educate...

  • FDA recognises OxyContin's abuse-deterrent properties.  // Reactions Weekly;4/20/2013, Issue 1449, p4 

    The article reports that the updated labeling for reformulated controlled-release oxycodone (OxyContin ER) of Purdue Pharma, has been approved by the U.S. Food and Drug Administration (USDA) in April 2013.

  • Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem: GAO-04-110.  // GAO Reports;12/19/2003, p1 

    Amid heightened awareness that many patients with cancer and other chronic diseases suffer from undertreated pain, the Food and Drug Administration (FDA) approved Purdue Pharma's controlled-release pain reliever OxyContin in 1995. Sales grew rapidly, and by 2001 OxyContin had become the most...

  • FDA advisory committees skeptical of new OxyContin abuse-resistance. Buono, Drew // Drug Store News;5/19/2008, Vol. 30 Issue 6, p5 

    The article outlines the evaluation made by the U.S. Food and Drug Administration (FDA) on Purdue Pharma's OxyContin, a painkiller. Two of FDA's advisory committees are not convinced that the institution provided sufficient scientific data on the abuse-resistance of the drug. Purdue is seeking...

  • Purdue's problems mount. Strempel, Dan // Westchester County Business Journal;8/1/2005, Vol. 44 Issue 31, p9 

    The article reports that the U. S. Food and Drug Administration (FDA) has requested Purdue Pharma LP to suspend the marketing of Palladone, a pain medication, after the loss of its patent protection on drug OxyContin in New York The request of FDA has affected the operations of Purdue. In fact,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics